



Presentation to Bell Potter Healthcare Coference

Dr James Garner Chief Executive Officer

Sydney, NSW 10 November 2021

ASX: KZA | NASDAQ: KZIA | Twitter: @KaziaTx

Forward-Looking Statements

This presentation contains **forward-looking statements** within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve substantial risks and uncertainties, not all of which may be known at the time. All statements contained in this presentation, other than statements of historical fact, including statements regarding our strategy, research and development plans, collaborations, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. Not all forward-looking statements in this presentation are explicitly identified as such.

Many factors could cause the actual results of the Company to differ materially from the results expressed or implied herein, and you should not place undue reliance on the forward-looking statements. Factors which could change the Company's expected outcomes include, without limitation, our ability to: advance the development of our programs, and to do so within any timelines that may be indicated herein; the safety and efficacy of our drug development candidates; our ability to replicate experimental data; the ongoing validity of patents covering our drug development candidates, and our freedom to operate under third party intellectual property; our ability to obtain necessary regulatory approvals; our ability to enter into and maintain partnerships, collaborations, and other business relationships necessary to the progression of our drug development candidates; the timely availability of necessary capital to pursue our business objectives; and our ability to attract and retain qualified personnel; changes from anticipated levels of customer acceptance of existing and new products and services and other factors.

Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can therefore be no assurance that such expectations will prove to be correct. The Company has no obligation as a result of this presentation to clinical trial outcomes, sales, partnerships, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, or marketing existing products.

In addition, the extent to which the COVID-19 outbreak continues to impact our workforce and our discovery research, supply chain and clinical trial operations activities, and the operations of the third parties on which we rely, will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, additional or modified government actions, and the actions that may be required to contain the virus or treat its impact.

Any forward-looking statements contained in this presentation speak only as of the date this presentation is made, and we expressly disclaim any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.



Company Overview

An oncology drug-development company



Lead Program in Phase III for Glioblastoma

Paxalisib

- Under development for glioblastoma, most common and aggressive form of brain cancer
- International phase III underway
- Developed by Genentech, Inc
- US\$ 1.5 billion target market
- Eight further studies ongoing across various forms of brain cancer
- Commercial partnership in place with Simcere Pharmaceutical for Greater China region



Diversified Clinical-Stage Pipeline

EVT801

- Under development for advanced cancer (lung, liver, kidney, and other cancers are future targets)
- Phase I study underway in France
- Developed by Sanofi and Evotec SE
- Targets lymphangiogenesis, and shows preclinical evidence of synergy with immuno-oncology therapies




Strong Corporate Fundamentals

- Listed on ASX (KZA) and on NASDAQ (KZIA)
- ~AU\$ 200 million market cap.
- Cash position @ 30 Sept 2021: ~AU\$ 19.6 million
- Lean operating model, with ~75% of cashflow devoted directly to clinical trials
- Multiple fundamental-driven
 institutional investors on registry




2021 in Review *A Year of Achievements*





Pipeline


Two world-class assets in clinical trials by end CY2021





Operating Model

In-licensing advanced assets drives earlier value realization





Financial Metrics *Value-driving news flow for investors*




Market Capitalisation	AU\$ 200M
Listing	
ASX (primary)	KZA
NASDAQ (ADSs @ 1:10 ratio)	KZIA
Shares on Issue	130M
Balance Sheet	AU\$
Cash (at 30 Jun 21)	\$19.6M
Monthly Burn Rate	~\$1.25M
Substantial Shareholders	
Willoughby Capital	16%
Quest Asset Partners	9%
Platinum Asset Management	6%

Board and Management



2%

Kazia's enterprise value has increased by approximately 37x in the last five years





Source: Company Annual Reports; Marketwatch

CY2021 Milestones and Newsflow

Multiple catalysts across two clinical programs

Commence of recruitment to GBM AGILE pivotal study for paxalisib	January 2021	\checkmark
Out-license of Cantrixil legacy asset to Oasmia Pharmaceutical	March 2021	\checkmark
Partnership for paxalisib in Greater China with Simcere Pharmaceutical	March 2021	\checkmark
Paxalisib interim phase II glioblastoma data at AACR Annual Meeting	April 2021	\checkmark
Global in-license of EVT801 from Evotec SE	April 2021	\checkmark
Commence recruitment to paxalisib phase II PCNSL study at Dana-Farber	June 2021	✓
Commence recruitment to PNOC paxalisib combination study in DIPG	2H CY2021	
Initial interim data from paxalisib phase II BCBM trial at Dana-Farber	2H CY2021	
Initial interim data from paxalisib phase II brain mets study by Alliance Group	2H CY2021	
Initial interim data from paxalisib phase I brain mets study at Sloan-Kettering	2H CY2021	
Final data from paxalisib phase II glioblastoma trial	2H CY2021	
Commence recruitment to EVT801 phase I trial	Nov 2021	\checkmark

Italics - updated guidance

Note: all guidance is indicative, and subject to amendment in light of changing conference schedules, operational considerations, etc.




Paxalisib

Brain Cancer Phase III




Treatment of brain cancer has improved little in recent decades, unlike other cancers





Paxalisib was designed specifically to overcome key challenges in the treatment of brain cancer



Oral Presentation

15mg capsule, taken once daily; no significant food effect

Strong IP Protection

Composition-of-matter to 2031 in most jurisdictions

Low Cost of Goods


Straightforward manufacture with excellent stability at controlled ambient

Limited Potential for Interactions

Has been successfully combined with other targeted therapies and RTx




Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer





Temozolomide is only FDA-approved drug for GBM; it is ineffective in ~65% of cases




Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003

Note: Temozolomide is only approved therapy for newly-diagnosed patients; Avastin (bevacizumab) is approved for use in recurrent setting



The PI3K / Akt / mTOR pathway is a critical signalling mechanism for many tumor types




Comparative Potency vs Other PI3K Inhibitors					
	IC ₅₀ (nM	IC ₅₀ (nM)			
	p110α	p110β	p110γ	p110δ	mTORC 1/2
Paxalisib	2	46	10	3	70
Idelalisib	820	565	89	2.5	>1,000
Alpelisib	5	1200	250	290	>9,100
		166	262	116	4,600
Pilaralisib	39	383	23	36	>15,000
Taselisib	0.3	9.1	1.0	0.1	1,200
Pictilisib	3	33	75	3	580

Note: lower IC_{50} implies more potent activity Source: HF Zhao et al. (2017) *Molecular Cancer*. 16:100




The PI3K inhibitor class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier





Latest phase II data compares well to historical data for temozolomide (existing standard of care)



Presented at Society for Neuro-Oncology Annual Meeting, November 2020

Note: figures for existing therapy are for temozolomide, per Hegi et al. (2005); comparison between different studies is never perfectly like-for-like



Toxicities are generally mild to moderate, entirely reversible, and manageable with readily-available therapies

Term	Gr 1	Gr 2	Gr 3	Gr 4	Total (%)
Rash	4	6	7		17 (71%)
Fatigue	2	10	2		14 (58%)
Stomatitis	4	6	1		11 (46%)
Decreased appetite	5	5	1		11 (46%)
Nausea	3	5	1		9 (38%)
Hyperglycemia	1	2	5		8 (33%)
Diarrhea	5	1			6 (25%)
Decreased neutrophils	2	3		1	6 (25%)
Vomiting	3	2	1		6 (25%)
Decreased weight	3	2			5 (21%)
Decreased platelets	4	1			5 (21%)
Dehydration		4	1		5 (21%)
Dysgeusia		4			4 (17%)
Decr. lymphocytes	1	2			3 (13%)
Drug reaction			3		3 (13%)
Malaise	2	1			3 (18%)
Incr. cholesterol	2				2 (8%)
Pruritis	1		1		2 (8%)

Number of Patients at 60mg (n=24) Experiencing AEs 'Possibly' or 'Likely' Related to Paxalisib (affecting \geq 2 patients)

Presented at Society for Neuro-Oncology Annual Meeting, November 2020



Nine clinical studies are active across multiple forms of brain cancer


Registration	Indication	Phase	N	Status	Sponsor
Primary Brain Ca	ncer				
<u>NCT03522298</u>	Glioblastoma	II	30	Follow-up	
TBD	Glioblastoma (combination with ketogenic diet)	II	33-60	Start-up	Weill Cornell Medicine
<u>NCT03970447</u>	Glioblastoma (GBM AGILE)	II / III	Up to 200 on paxalisib	Recruiting	
<u>NCT03696355</u>	DIPG and DMGs	I	27	Follow-up	St. Jude Children's Research Hospital
TBD	DIPG and DMGs	II	TBD	Start-up	Pacific Pediatric Neuro-Oncology Consortium
<u>NCT04906096</u>	Primary CNS Lymphoma	II	25	Recruiting	DANA-FARBER
Secondary (Meta	static) Brain Cancer				
<u>NCT04192981</u>	Brain Metastases (combination with radiotherapy)	I	Up to 36	Recruiting	Memorial Sloan Kettering Cancer Center
<u>NCT03765983</u>	Breast Cancer Brain Metastases (combination with trastuzumab)	II	Up to 47	Recruiting	DANA-FARBER
<u>NCT03994796</u>	Brain Metastases ('Alliance' multi-drug study)	II	50	Recruiting	NIH NATIONAL CANCER INSTITUTE



GBM AGILE international pivotal study is underway, and is expected to provide the basis for regulatory approval

Key Points

- A 'platform study', run independently of individual companies, designed to expedite the approval of new drugs for glioblastoma
- Multiple drugs are evaluated in parallel, saving time and money
- Not a 'winner-takes-all' approach: multiple drugs can succeed
- Cutting-edge 'adaptive design' avoids redundant recruitment, expediting path to market
- Strong support from FDA and key opinion leaders




eliminating redundancy

Economies of scale due to multiple participating drugs allows for large site pool, robust study infrastructure, and reduced cost

Primary endpoint is overall survival (OS), the 'gold standard' for approval of new cancer drugs



Commercial opportunity is substantial, with one commercial partnership already in place





Key Points

- 1
- Well-understood mechanism (PI3K inhibition) but unique differentiating feature (brain penetration)
- Positive phase II data in glioblastoma, supported by very strong preclinical package and positive phase I data
- 3 Fully-funded international registration study underway with support of FDA and leading clinicians
- 4
- Broad trial program underway with world-class centres in other forms of brain cancer; de-risks lead indication
- 5
- Targeting a US\$ 1.5B market for glioblastoma alone, with limited competition and very high unmet-need



EVT801

Solid Tumors Pre-Phase I




Targeting angiogenesis is a well-established approach in the treatment of cancer

Product	Company	Target	Indications	Annual Sales (US\$)*
AVASTIN° bevacizumab	Genentech A Member of the Roche Group	VEGF-A	Colorectal cancerLung cancerBreast cancer	\$7 billion
(sorafenib) tablets	BAYER	VEGFR PDGFR RAF kinases	 Hepatocellular carcinoma Renal call carcinoma Thyroid cancer 	\$1 billion
SUTENT sunitinib malate	P fizer	VEGFR PDGFR	Renal cell carcinomaGasto-intestinal stromal tumor	\$750 million
Votrient [®] pazopanib tablets (200 mg)	ပံ novartis	VEGFR PDGFR c-Kit	Renal cell carcinomaSoft tissue sarcoma	\$1 billion
Inlyta . axitinib _{ingenting} takes	P fizer	VEGFR c-Kit PDGFR	Renal cell carcinoma	\$400 million
	Eisai	VEGFR	 Renal cell carcinoma Hepatocellular carcinoma Endometrial carcinoma 	\$300 million
(cabozantinib) tablets	EXELIXIS	c-Met VEGFR2 RET	Renal cell carcinomaHepatocellular carcinoma	\$750 million




Despite their proven efficacy, angiogenesis inhibitors are limited by several key challenges





EVT801 is a selective VEGFR inhibitor, primarily inhibiting lymphangiogenesis (formation of new lymphatic vessels)






Preclinical data confirms activity of EVT801 (1/2) *Dramatic single-agent activity in DEN-induced HCC model*

Experimental Methods

- Syngeneic mouse model
- Hepatocellular carcinoma chemically induced with diethylnitrosamine (DEN)
- Treatment with EVT801 in M10-M12

Conclusions

- EVT801 monotherapy causes marked reduction in growth of primary tumor versus untreated comparator
- EVT801 appears to have significant anti-metastatic effect



* Statistically significant (p<0.05)



Data on file


Preclinical data confirms activity of EVT801 (2/2) *Synergistic activity in combination with anti-CTLA4 mAb*

Experimental Methods

- Orthotopic mouse model
- 4T1 tumor cells inoculated in BALB/c mice (mammary fat pad)
- Treatment with EVT801 on D7-D21 and with anti-CTLA4 on D7, D14, D21

Conclusions

- EVT801 monotherapy has approximately equivalent activity to anti-CTLA4 antibody
- Combination of EVT801 and anti-CTLA4 antibody is highly synergistic



Note: CTLA4 is the target of Yervoy[®] (ipilimumab), an approved immuno-oncology therapy



Data on file

Kazia commenced a phase I clinical trial in November 2021



Up to 60 patients with advanced solid tumors, resistant to existing therapies



Endpoints will include safety and tolerability, mechanism of action, and preliminary efficacy



EVT801 administered initially as monotherapy; plan for early transition to immunotherapy combination



Rich suite of biomarkers investigated to provide deep understanding of EVT801 activity

-0-	-U-
FF	Ħ

First Patient In (FPI) November 2021

Current Status	
 Investigational product manufactured and ready to ship 	\checkmark
 Draft clinical trial protocol prepared and under discussion with clinicians 	\checkmark
 Preclinical toxicology package complete for phase I 	\checkmark
 Regulatory documentation prepared 	\checkmark
 Biomarker assays in advanced development 	\checkmark
 Two sites in EU selected to commence phase I study 	\checkmark
CRO selected for phase I study	\checkmark



Key Points

- 1
- Well-understood mechanism (anti-angiogenesis) but unique differentiating feature (VEGFR3 selectivity)
- 2 Very strong preclinical data package, with evidence of activity in multiple tumors and favourable toxicology
- 3 High potential for combination use with immunooncology therapies
- 4
- 'Clinic-ready', with phase I study anticipated to start in CY2021
- 5 Substantially diversifies Kazia pipeline beyond PI3K and beyond brain cancer





www.kaziatherapeutics.com info@kaziatherapeutics.com